A Replication-Defective Myxoma Virus Inducing Pro-Inflammatory Responses as Monotherapy and an Adjuvant to Chemo- and DC Immuno-Therapy for Ovarian Cancer
Viruses · 29.07.2025 · 17 (8) · 1058
DOI: 10.3390/v17081058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 29.07.2025. Verfasst von Martin J Cannon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA. Hauptthemen laut MEDLINE: Myxoma virus, Ovarian Neoplasms, Dendritic Cells, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Myxoma virus (MYXV), a rabbit-specific poxvirus and non-pathogenic in humans and mice, is an excellent candidate oncolytic virus for cancer therapy. MYXV also has immunotherapeutic benefits. In ovarian cancer (OC), immunosuppressive tumor-associated macrophages (TAMs) are key to inhibiting antitumor immunity while hindering therapeutic benefit by chemotherapy and dendritic cell (DC) vaccine. Because MYXV favors binding/entry of macrophages/monocytes, we examined the therapeutic potential of MYXV against TAMs. We found previously that a replication-defective MYXV with targeted deletion of an essential gene, M062R, designated ΔM062R MYXV, activated both the host DNA sensing pathway and the SAMD9 pathway. Treatment with ΔM062R confers therapeutic benefit comparable to that of wild-type replicating MYXV in preclinical models. Here we found that ΔM062R MYXV, when integrated with cisplatin and DC immunotherapy, further improved treatment benefit, likely through promoting tumor antigen-specific T cell function. Moreover, we also tested ΔM062R MYXV in targeting human immunosuppressive TAMs from OC patient ascites in a co-culture system. We found that ΔM062R treatment subverted the immunosuppressive properties of TAMs and elevated the avidity of cytokine production in tumor antigen-specific CD4+ T cells. Overall, ΔM062R presents a promising immunotherapeutic platform as a beneficial adjuvant to chemotherapy and DC vaccine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA.
ORCID-Profile: Martin J Cannon, Jia Liu
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NIH HHS
- NIH
- UAMS
- UAMS VCRI pioneer
- River Valley Ovarian Cancer Alliance Research
- NIH National Institute of General Medical Sciences Centers of Biomedical Research Excellence
Zitieren
APA
Cannon, M. J., & Liu, J. (2025). A Replication-Defective Myxoma Virus Inducing Pro-Inflammatory Responses as Monotherapy and an Adjuvant to Chemo- and DC Immuno-Therapy for Ovarian Cancer. Viruses, 17(8), 1058. https://doi.org/10.3390/v17081058
Vancouver
Cannon MJ, Liu J. A Replication-Defective Myxoma Virus Inducing Pro-Inflammatory Responses as Monotherapy and an Adjuvant to Chemo- and DC Immuno-Therapy for Ovarian Cancer. Viruses. 2025;17(8):1058. doi:10.3390/v17081058
BibTeX
@article{Cannon2025,
author = {Cannon, Martin J and Liu, Jia},
title = {A Replication-Defective Myxoma Virus Inducing Pro-Inflammatory Responses as Monotherapy and an Adjuvant to Chemo- and DC Immuno-Therapy for Ovarian Cancer},
journal = {Viruses},
year = {2025},
volume = {17},
number = {8},
pages = {1058},
doi = {10.3390/v17081058}
}
EUVIMED